Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Apr;42(4):947-50.
doi: 10.1128/AAC.42.4.947.

Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay

Affiliations

Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay

R W Murray et al. Antimicrob Agents Chemother. 1998 Apr.

Abstract

Oxazolidinone-resistant mutants of Staphylococcus aureus, isolated with a spiral plating technique, had a 16-fold higher MIC (2 versus 32 microg/ml) of eperezolid when compared to the parental sensitive strain. Eperezolid inhibited in vitro protein translation with 50% inhibitory concentrations of 30 microM for the oxazolidinone-sensitive S30 extract and 75 microM for the resistant extract. Experiments mixing various combinations of S100 and crude ribosome preparations from oxazolidinone-sensitive and -resistant S. aureus strains in a transcription-translation assay demonstrated that the resistant determinant resided within the ribosomal fraction. Ribosomes from the oxazolidinone-resistant strain bound less drug than ribosomes from the sensitive strain, indicating that the ribosome is the site of action for the oxazolidinones. These experiments demonstrate that an alteration of the ribosome is responsible for some or all of the oxazolidinone resistance observed in the S. aureus mutant.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Effect of eperezolid on activity of S30 extracts from Oxas and Oxar strains in the S. aureus in vitro TT assay. Percent [35S]methionine incorporation in TCA-precipitable material in the presence of increasing concentrations of eperezolid. •, SA31552 (Oxas); ▪, SA31593 (Oxar).
FIG. 2
FIG. 2
Reconstitution of S. aureus TT in the presence of increasing concentrations of eperezolid (0 to 300 μM) with S100 and crude ribosome preparations from SA31552 and SA31593 in the S. aureus in vitro TT assay. Measuring TCA-precipitable [35S]methionine incorporation. (A) S100 from the sensitive strain mixed with crude ribosomes from either the sensitive or the resistant strain. •, Oxas S100, Oxar ribosomes; □, Oxas S100, Oxas ribosomes. (B) S100 from the resistant strain mixed with crude ribosomes from either the sensitive or resistant strain. , Oxar S100, Oxar ribosomes; ◊, Oxar S100, Oxas ribosomes.
FIG. 3
FIG. 3
Binding of [14C]eperezolid to increasing concentrations of purified, high-salt-washed Oxas and Oxar ribosomes. Specific binding is calculated as the total binding minus the nonspecific binding. Nonspecific binding represents the binding reaction in the presence of a 300-fold molar excess of cold drug competitor. Error bars indicate standard deviations (n = 3). □, total eperezolid binding; ▨, specific eperezolid binding.

Similar articles

Cited by

References

    1. Barbachyn M R, Hutchinson D K, Brickner S J, Cynamon M H, Kilburn O J, Klemens S P, Glickman S E, Grega K C, Hendges S K, Toops D S, Ford C W, Zurenko G E. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem. 1996;39:680–685. - PubMed
    1. Barry A L. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents. Antimicrob Agents Chemother. 1988;32:150–152. - PMC - PubMed
    1. Brickner S J, Hutchinson D K, Barbachyn M R, Manninen P R, Ulanowicz D A, Garmon S A, Grega K C, Hendges S K, Toops D S, Ford C W, Zurenko G E. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996;39:673–679. - PubMed
    1. Brumfitt W, Hamilton-Miller J M T. Antibacterial oxazolidinones: in vitro activity of a new analogue, E3709. Diagn Microbiol Infect Dis. 1992;15:621–625. - PubMed
    1. Daly J S, Eliopoulos G M, Reiszner E, Moellering R C. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. Antimicrob Agents Chemother. 1988;21:721–730. - PubMed